Amicus Therapeutics Inc

FOLD

14.300USD

+0.020+0.14%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Amicus Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

77 / 392

Overall Ranking

198 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Amicus Therapeutics Inc Highlights

StrengthsRisks

Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 60.46% year-on-year.

Undervalued

The company’s latest PE is -320.70, at a low 3-year percentile range.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.90K shares of this stock.

Analyst Rating

Based on 8 analysts

Hold

Current Rating

15.500

Target Price

+8.54%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Amicus Therapeutics Inc is 8.88, ranking 24 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 169.06M, representing a year-over-year increase of 19.46%, while its net profit experienced a year-over-year increase of 357.19%.

Score

Industry at a Glance

Previous score

8.88

Change

0



Financials

7.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.41

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.73

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Amicus Therapeutics Inc is 7.84, ranking 78 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -320.70, which is -95.84% below the recent high of -13.33 and -0.56% above the recent low of -322.49.

Score

Industry at a Glance

Previous score

7.84

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 77/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Amicus Therapeutics Inc is 6.25, ranking 339 out of 392 in the Biotechnology & Medical Research industry. The average price target is 16.00, with a high of 22.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

6.25

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Amicus Therapeutics Inc is 3.97, ranking 356 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 14.37 and the support level at 14.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.83

Change

0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Amicus Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 109.22%, representing a quarter-over-quarter decrease of 0.82%. The largest institutional shareholder is The Vanguard, holding a total of 29.63M shares, representing 9.44% of shares outstanding, with 0.23% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

30.87M

+4.73%

Wellington Management Company, LLP

28.63M

-1.70%

BlackRock Institutional Trust Company, N.A.

21.54M

-1.74%

William Blair Investment Management, LLC

15.75M

+7.56%

Avoro Capital Advisors LLC

15.03M

-16.53%

Millennium Management LLC

11.81M

+59.13%

State Street Investment Management (US)

11.56M

-0.04%

Vestal Point Capital, LP

9.75M

-18.07%

Citadel Advisors LLC

8.25M

+38.09%

Point72 Asset Management, L.P.

Star Investors

7.16M

+118.25%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Amicus Therapeutics Inc is 5.00, ranking 60 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.43. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Amicus Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Amicus Therapeutics Inc

FOLD

6.94 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment